Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.35 |
| ▸ | PPARG | P37231 | 10/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762603 | 0.90 | PPARA (0.39) | PPARAPPARGNPC1RAB9AS1PR1 | |
| SCHEMBL3758105 | 0.88 | PPARA (0.38) | PPARAPPARGNPC1RAB9AS1PR1 | |
| SCHEMBL3769108 | 0.88 | NPC1 (0.41) | PPARAPPARGNPC1RAB9AALDH1A1 | |
| SCHEMBL3764480 | 0.88 | PPARA (0.46) | PPARAPPARGS1PR1 | |
| SCHEMBL3763466 | 0.88 | PPARA (0.47) | PPARAPPARGNPC1RAB9A | |
| SCHEMBL3763331 | 0.88 | PPARA (0.41) | PPARAPPARGS1PR1S1PR3 | |
| SCHEMBL3763512 | 0.88 | PPARA (0.38) | PPARAPPARGNPC1RAB9AALDH1A1 | |
| SCHEMBL3764578 | 0.87 | PPARA (0.47) | PPARAPPARGS1PR1ALDH1A1 | |
| SCHEMBL3764540 | 0.87 | PPARA (0.47) | PPARAPPARG | |
| SCHEMBL3764542 | 0.87 | PPARA (0.47) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268867-B2 | 1,3-dioxane carboxylic acids | CADILA HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-20100311795-A1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-09 | — | — | US | claimed |
| EP-1989192-B1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LTD (IN) | 2009-07-22 | — | — | EP | claimed |
| US-8268867-B2 | 1,3-dioxane carboxylic acids | CADILA HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| US-20100311795-A1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-1989192-B1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LTD (IN) | 2009-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311795-A1 | 1,3-DIOXANE CARBOXYLIC ACIDS | SLC10A1, CYP11B2, UGT1A1 | PPARA 1132/4885PPARG 636/4885NPC1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.